Ogden Christopher
SEC CIK 1914523 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | SVP, Fin, Accounting | 295.3K | — | $179.9K | 16 | 2023-02-02 | 2026-06-15 |
Most active insiders at CTMX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | McCarthy Sean A. | CEO, Dir | — | $1.23M |
| 2 | BELVIN MARCIA | SVP, CSO | — | $202.2K |
| 3 | Chu Yu-Waye | Chief Medical Off | — | $136.6K |
| 4 | Ogden Christopher | CFO | — | $129.0K |
| 5 | Lester Rachael | Chief Business Off | — | — |
| 6 | Carvajal Alejandra | CLO | — | — |
Transactions 16
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-17 18:38 | 2026-06-15 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | CFO | S - Sale | $3.05 | -1,624 | 295.3K | -0.5% | -$4,953 | |
| 2026-03-19 | 2026-03-17 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | CFO | S - Sale | $6.42 | -19.3K | 296.9K | -6% | -$124.1K | |
| D | 2026-02-04 | 2026-02-02 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | CFO | A - Grant | $0.00 | +90.0K | 316.3K | +40% | $0 |
| D | 2025-06-17 | 2025-06-13 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | CFO | M - OptEx | $0.00 | +37.5K | 236.9K | +19% | $0 |
| DM | 2025-06-17 | 2025-06-13+ | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | CFO | S - Sale+OE | $2.72 | -12.3K | 199.4K | -6% | -$33.4K |
| 2025-03-20 | 2025-03-18 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | CFO | S - Sale | $0.6 | -8,551 | 201.0K | -4% | -$5,131 | |
| DM | 2025-02-06 | 2025-02-04 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | CFO | A - Grant | $0.00 | +101.5K | 209.6K | +94% | $0 |
| D | 2024-08-22 | 2024-08-20 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | CFO | M - OptEx | $0.00 | +6,875 | 110.1K | +7% | $0 |
| D | 2024-08-22 | 2024-08-20 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | CFO | S - Sale+OE | $1.23 | -1,984 | 108.1K | -2% | -$2,440 |
| D | 2024-06-14 | 2024-06-12 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | CFO | A - Grant | $0.00 | +17.5K | 103.2K | +20% | $0 |
| 2024-03-21 | 2024-03-19 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | SVP, Fin, Accounting | S - Sale | $2.09 | -2,971 | 85.7K | -3% | -$6,209 | |
| D | 2024-01-19 | 2024-01-18 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | SVP, Fin, Accounting | A - Grant | $0.00 | +40.0K | 88.7K | +82% | $0 |
| 2023-12-22 | 2023-12-20 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | SVP, Fin, Accounting | S - Sale | $1.38 | -1,990 | 48.7K | -4% | -$2,746 | |
| D | 2023-12-19 | 2023-12-17 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | SVP, Fin, Accounting | M - OptEx | $0.00 | +6,875 | 50.6K | +16% | $0 |
| 2023-03-20 | 2023-03-16 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | SVP, Fin, Accounting | S - Sale | $1.98 | -516 | 37.8K | -1% | -$1,022 | |
| D | 2023-02-06 | 2023-02-02 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | SVP, Fin, Accounting | A - Grant | $0.00 | +25.0K | 38.3K | +188% | $0 |
Purchase Sale Sale after option exercise All abbreviations